Comparison of Body Composition Changes With Weight Loss Interventions

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
Vanderbilt University Medical Center
Study ID
NCT07115069
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • GLP-1 receptor agonist — DRUG
    Any FDA-approved GLP-1 receptor agonist
  • Gastric Bypass Surgery (laparoscopic) — PROCEDURE
    Patients undergo laparoscopic gastric bypass with a roux limb between 75 - 150 cm and biliopancreatic limb between 50 - 150 cm as determined by the primary surgeon.
  • Gastric Bypass Surgery (robotic) — PROCEDURE
    Patients undergo robotic gastric bypass with a roux limb between 75 - 150 cm and biliopancreatic limb between 50 - 150 cm as determined by the primary surgeon.

Study Details

This study is being done to compare the effects of a newer class of weight loss medications to weight loss surgery on the body's muscle, metabolism, and side effects over time. People with severe obesity often lose weight using either medications like GLP-1 receptor agonists (such as semaglutide or tirzepatide) or by having bariatric surgery, such as gastric bypass. While both approaches can lead to weight loss, they may affect the body in different ways. The investigators are inviting adult patients who are planning to either start one of these weight loss medications or undergo gastric bypass surgery to join this study. Participants will be asked to complete four body composition scans (called DXA scans) over the course of a year-at the beginning of the study and again at 3, 6, and 12 months. These scans will help us measure changes in fat and muscle. Participants will also complete surveys and provide information on side effects, such as nausea or fatigue, that may affect their eating or activity levels. The investigators' goal is to better understand how different weight loss treatments impact not just weight, but also muscle mass, energy levels, and side effects. This information may help doctors and patients choose the most appropriate treatment in the future.

Key Dates

Start date
Aug 9, 2025
Status verified
Aug 2025
Primary completion
Sep 30, 2026
Completion
Jan 31, 2027

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: GLP-1 Receptor Agonists Arm
    Patient recieving Glucagon Like Peptide 1 Receptor Agonists (GLP1RA) or incretin polyagonists.
  • Arm: Gastric Bypass surgery (laparoscopic)
    Patients undergoing gastric bypass laparoscopically
  • Arm: Gastric Bypass surgery (robotic)
    Patients undergoing Gastric Bypass surgery robotically

Primary Outcome Measure

Skeletal Muscle Loss [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Vanderbilt University Medical CenterNashvilleTennessee37232-

Find similar trials in Nashville, TN

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Vanderbilt University Medical Center· Nashville, TN

Related Studies